TOP HEADLINES

Featured Story

  • Pfizer continues to explore virtual trials with 23andMe pact

    Pfizer and 23andMe have teamed up to identify genetic factors linked to inflammatory bowel disease. And with 23andMe trumpeting the fact that people can participate without leaving their homes, the study represents a continuation of Pfizer's interest in virtual trials.

Jazz Pharmaceuticals joins AstraZeneca and Lilly on Box's client list

Jazz Pharmaceuticals and Boston Scientific have begun using Box as their main platform for managing and collaborating on content.

Illumina teams with AstraZeneca, J&J and Sanofi on cancer diagnostic

Illumina has laid the groundwork for increased use of next-generation sequencing in clinical research by striking a deal with Big Pharma, which could result in the company disrupting diagnostics using its dominance in NGS.

Rollout of openFDA continues with drug labeling, medtech adverse event APIs

Having committed to a fast rollout of APIs at the start of the summer, the FDA made good on its promise this week by making data on drug labeling available. And the regulator went beyond its initial commitment by releasing an API for medical device adverse events.

uBiome raises $4.5M as first batch of Y Combinator biotechs pitch to investors

The first batch of Y Combinator-backed life science companies made their pitches at the incubator's Demo Day this week. And with one of the startups already bagging $4.5 million from angel investors, Y Combinator is optimistic it can continue to expand into healthcare.

Clinverse and Comprehend raise $30M in separate financing rounds

Clinverse and Comprehend have raised a total of $30.1 million in separate Series C and B financing rounds, giving both companies the cash to push ahead with their expansion plans.

MORE NEWS

From Our Sister Sites

FierceBiotech

The development team from Sanofi and Regeneron journeyed to the ESC Congress in Barcelona this weekend to detail the impact their late-stage PCSK9 drug alirocumab has on bad cholesterol, drawing some...

FierceBiotech

Novartis told the world back in March that its experimental heart drug LCZ696 had delivered the goods early in a pivotal study, allowing for a quick wrap of the Phase III trial. And today the pharma...